AU Patent

AU2022422597A1 — Drug delivery system comprising monomethyl fumarate

Assigned to Gencaps Sarl · Expires 2024-07-11 · 2y expired

What this patent protects

A sustained release drug delivery system comprising a monolithic solid polyethylene glycol (PEG) matrix and monomethyl fumarate (MMF) characterized by the following conditions: - the MMF being dispersed under solid state in the said matrix, and - the system comprising from 50% to…

USPTO Abstract

A sustained release drug delivery system comprising a monolithic solid polyethylene glycol (PEG) matrix and monomethyl fumarate (MMF) characterized by the following conditions: - the MMF being dispersed under solid state in the said matrix, and - the system comprising from 50% to 60% w/w of MMF. Said system for use in the treatment of an autoimmune disease wherein the autoimmune disease is preferably psoriasis or multiple sclerosis.

Drugs covered by this patent

Patent Metadata

Patent number
AU2022422597A1
Jurisdiction
AU
Classification
—
Expires
2024-07-11
Drug substance claim
No
Drug product claim
No
Assignee
Gencaps Sarl
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.